2923-LB: A Remote Program for Navigator- and Pharmacist-Led Implementation of Obesity Medications

Introduction and Objective: There is urgent need for effective and scalable obesity care strategies. We evaluated whether a remote, algorithmic, navigator- and pharmacist-led program enhances obesity medication (OM) implementation. Methods: Participants were recruited via survey from an ongoing program evaluating a digital lifestyle intervention (RestoreHealth). Eligibility criteria included 1) BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with ≥1 obesity-related condition; 2) no current use of OMs; and 3) either an increase in body weight by 3 months, or 3.2 kg body weight reduction by 6 months, after initiation of RestoreHealth. Persons eligible for but declined the OM intervention served as a control group. OMs were prescribed by a pharmacist. The primary outcome was OM prescription over a maximum of 9 months. Results: Of 200 survey respondents, 99 were eligible (mean age, 50±12 years; mean BMI, 36±6 kg/m2). Of these, 75 (76%) enrolled in the OM intervention and 24 (24%) continued with RestoreHealth alone. Overall, 93.3% of the participants in the OM intervention, vs. 8.3% of control participants, received ≥1 OM prescription (Pcomparsion0.001). GLP-1RA-based therapies were most prescribed. Participants receiving the OM intervention were more likely to initiate ≥1 OMs and had greater body weight reduction after 6 months vs. control (Figure). Conclusion: Remote management of OMs by navigators and pharmacists may represent an effective and scalable strategy to improve obesity care. Disclosure J. Ostrominski: Advisory Panel; Current; Corcept Therapeutics. K.B. Wagholikar: None. B.E. Falahee: None. M. Tucci: None. H. Nichols: Advisory Panel; Current; ReCor Medical, Inc. Consultant; Ended; Elsevier. C. Cannon: Research Support; Current; Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk. Other - Research Grants from: Amgen, Better Therapeutics, Boehringer-Ingelheim (BI), Novo Nordisk, and salary support from Colorado Prevention Center (CPC) Clinical Research, which gets research grant support from Amgen, Bayer, Cleerly, Esperion, Lexicon, Silence.; Current; Research Grants from: Amgen, Better Therapeutics, Boehringer-Ingelheim (BI), Novo Nordisk, and salary support from Colorado Prevention Center (CPC) Clinical Research, which gets research grant support. Consultant; Current; Amgen Inc., Amryt Pharma Plc, Applied Therapeutics, Boehringer Ingelheim International GmbH. Other - Consulting fees from Amryt/Chiesi, Amgen, Applied Therapeutics, BI, BMS, CSL Behring, Genomadix, Lilly, Janssen, Milestone, Novartis, Pfizer, Rhoshan, Tremeau; Current; Consulting fees from Amryt/Chiesi, Amgen, Applied Therapeutics, BI, BMS, CSL Behring, Genomadix, Lilly, Janssen, Milestone, Novartis, Pfizer, Rhoshan, Tremeau. Other - I serve on Data and Safety Monitoring Boards for the Areteia, Cortera, Novartis, Novo Nordisk, ROMTherapy, Inc. and the Veterans Administration.; Current; I serve on Data and Safety Monitoring Boards for the Areteia, Cortera, Novartis, Novo Nordisk, ROMTherapy, Inc. and the Veterans Administration. J. Plutzky: Consultant; Current; Amgen Inc., Boehringer Ingelheim International GmbH, Corcept Therapeutics, Merck Current; Amgen Inc., Novo Nordisk, Merck Current; AstraZeneca. Research Support; Current; Merck Current; Boehringer Ingelheim International GmbH. Consultant; Ended; Alnylam Pharmaceuticals, Inc. Consultant; Current; Medscape. Other - Consultant and grant support; Ended; Novo Nordisk. Consultant; Current; Milestone Therapeutics, Corcept Therapeutics. Stock/Shareholder; Current; AIwithCare, Knownwell, Signum Technologies.